Collaborate Explore Discover

Kee, Barbara PhDDias S, Xu W, McGregor S, Kee B. Transcriptional regulation of lymphocytedevelopment. Curr Opin Genet Dev. Curr Opin Genet Dev 18(5):441-8, 2008.* Dias S, Mansson R, Gurbuxani S, Sigvardsson M, Kee BL. E2A ProteinsPromote Development of Lymphoid-Primed Multipotent Progenitors.Immunity 29(2):217-27, 2008.Bhalla S, Spaulding C, Brumbaugh RL, Zagort DE, Massari ME, Murre C, KeeBL. differential roles for the E2A activation domains in B lymphocytes andmacrophages. J Immunol 180(3):1694-703, 2008.Gao J, Graves S, Koch U, Liu S, Jankovic V, Buonamici S, El Andaloussi A,Nimer SD, Kee BL, Taichman R, Radtke F, Aifantis I. Hedgehog signaling isdispensable for adult hematopoietic stem cell function. Cell Stem Cell 4(6):548-58, 2009.Kee BL, Dias S. A s-myly route toward lymphoid differentiation. Immunity30(4):474-6, 2009.Kee BL. E and ID proteins branch out. Nat Rev Immunol 9(3):175-84, 2009.Larson, Richard MD* # Ellis NA, Huo D, Yildiz O, Worrillow LJ, Banerjee M, Le Beau MM, LarsonRA, Allan JM, Onel K. MDM2 SNP309 and TP53 Arg72Pro interact to altertherapy-related acute myeloid leukemia susceptibility. Blood 112(3):741-9, 2008.Larson R. Allogeneic hematopoietic cell transplantation for adults with ALL.Bone Marrow Transplant 42 Suppl 1:S18-S24, 2008.Metzeler KH, Hummel M, Bloomfield CD, Spiekermann K, Braess J, SauerlandMC, Heinecke A, Radmacher M, Marcucci G, Whitman SP, Maharry K,Paschka P, Larson RA, Berdel WE, Buchner T, Wormann B, Mansmann U,Hiddemann W, Bohlander SK, Buske C. An 86 probe set gene expressionsignature predicts survival in cytogenetically normal acute myeloid leukemia.Blood 112(10):4193-201, 2008.* Baer MR, George SL, Caligiuri MA, Sanford BL, Bothun SM, Mrozek K,Kolitz JE, Powell BL, Moore JO, Stone RM, Anastasi J, Bloomfield CD, LarsonRA. Low-dose interleukin-2 immunotherapy does not improve outcomeof patients age 60 years and older with acute myeloid leukemia in firstcomplete remission: Cancer and Leukemia Group B Study 9720. J Clin Oncol26(30):4934-9, 2008.Paschka P, Marcucci G, Ruppert AS, Whitman SP, Mrozek K, Maharry K,Langer C, Baldus CD, Zhao W, Powell BL, Baer MR, Carroll AJ, CaligiuriMA, Kolitz JE, Larson RA, Bloomfield CD. Wilms’ tumor 1 gene mutationsindependently predict poor outcome in adults with cytogenetically normalacute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol26(28):4595-602, 2008.Hochhaus A, Baccarani M, Deininger M, Apperley JF, Lipton JH, Goldberg SL,Corm S, Shah NP, Cervantes F, Silver RT, Niederwieser D, Stone RM, DombretH, Larson RA, Roy L, Hughes T, Muller MC, Ezzeddine R, Countouriotis AM,Kantarjian HM. Dasatinib induces durable cytogenetic responses in patientswith chronic myelogenous leukemia in chronic phase with resistance orintolerance to imatinib. Leukemia 22(6):1200-6, 2008.Larson RA, Druker BJ, Guilhot F, O’Brien SG, Riviere GJ, Krahnke T,Gathmann I, Wang Y. Imatinib pharmacokinetics and its correlation withresponse and safety in chronic-phase chronic myeloid leukemia: a subanalysisof the IRIS study. Blood 111(8):4022-8, 2008.Le Beau, Michelle PhD* Li Z, Lu J, Sun M, Mi S, Zhang H, Luo RT, Chen P, Wang Y, Yan M, Qian Z,Neilly MB, Jin J, Zhang Y, Bohlander SK, Zhang DE, Larson RA, Le Beau MM,Thirman MJ, Golub TR, Rowley JD, Chen J. Distinct microRNA expressionprofiles in acute myeloid leukemia with common translocations. Proc NatlAcad Sci U S A 105(40):15535-40, 2008.* # Ellis NA, Huo D, Yildiz O, Worrillow LJ, Banerjee M, Le Beau MM, LarsonRA, Allan JM, Onel K. MDM2 SNP309 and TP53 Arg72Pro interact to altertherapy-related acute myeloid leukemia susceptibility. Blood 112(3):741-9, 2008.* Kirsammer G, Jilani S, Liu H, Davis E, Gurbuxani S, Le Beau MM, CrispinoJD. Highly penetrant myeloproliferative disease in the Ts65Dn mouse model ofDown syndrome. Blood 111(2):767-75, 2008.Mullighan CG, Miller CB, Radtke I, Phillips LA, Dalton J, Ma J, White D,Hughes TP, Le Beau MM, Pui CH, Relling MV, Shurtleff SA, Downing JR.BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros.Nature 453(7191):110-4, 2008.Qian Z, Chen L, Fernald AA, Williams BO, Le Beau MM. A critical role for Apcin hematopoietic stem and progenitor cell survival. J Exp Med 205(9):2163-75,2008.* Knight JA, Skol AD, Shinde A, Hastings D, Walgren RA, Shao J,Tennant TR, Banerjee M, Allan JM, Le Beau MM, Larson RA, GraubertTA, Cox NJ, Onel K. A genome-wide association study to identify novelloci associated with therapy-related myeloid leukemia susceptibility.Blood 113(22):5575-82, 2009.* Qian Z, Mao L, Fernald AA, Yu H, Luo R, Jiang Y, Anastasi J, Valk PJ,Delwel R, Le Beau MM. Enhanced expression of FHL2 leads to abnormalmyelopoiesis in vivo. Leukemia, 2009.Nachman, James MD* Stock W, La M, Sanford B, Bloomfield CD, Vardiman JW, Gaynon P,Larson RA, Nachman J. What determines the outcomes for adolescentsand young adults with acute lymphoblastic leukemia treated oncooperative group protocols? A comparison of Children’s Cancer Groupand Cancer and Leukemia Group B studies. Blood 112(5):1646-54, 2008.# Seibel NL, Steinherz PG, Sather HN, Nachman JB, Delaat C, EttingerLJ, Freyer DR, Mattano LA Jr, Hastings CA, Rubin CM, Bertolone K,Franklin JL, Heerema NA, Mitchell TL, Pyesmany AF, La MK, EdensC, Gaynon PS. Early postinduction intensification therapy improvessurvival for children and adolescents with high-risk acute lymphoblasticleukemia: a report from the Children’s Oncology Group. Blood111(5):2548-55, 2008.French D, Hamilton LH, Mattano LA Jr, Sather HN, Devidas M,Nachman JB, Relling MV. A PAI-1 (SERPINE1) polymorphism predictsosteonecrosis in children with acute lymphoblastic leukemia: a reportfrom the Children’s Oncology Group. Blood 111(9):4496-9, 2008.Odenike, Olatoyosi MD* # Stock W,Undevia SD,Bivins C,Ravandi F,Odenike O,Faderl S,RichE,Borthakur G,Godley L,Verstovsek S,Artz A,Wierda W,LarsonRA,Zhang Y,Cortes J,Ratain MJ,Giles FJ. A phase I and pharmacokineticstudy of XK469R (NSC 698215), a quinoxaline phenoxypropionic acidderivative, in patients with refractory acute leukemia. Invest New Drugs26(4):331-8, 2008.* Klisovic RB, Stock W, Cataland S, Klisovic MI, Liu S, Blum W, GreenM, Odenike O, Godley L, Burgt JV, Van Laar E, Cullen M, Macleod AR,Besterman JM, Reid GK, Byrd JC, Marcucci G. A phase I biological studyof MG98, an oligodeoxynucleotide antisense to DNA methyltransferase1, in patients with high-risk myelodysplasia and acute myeloid leukemia.Clin Cancer Res 14(8):2444-9, 2008.* Artz AS, Wickrema A, Dinner S, Godley LA, Kocherginsky M, OdenikeO, Rich ES, Stock W, Ulaszek J, Larson RA, van Besien K. PretreatmentC-reactive protein is a predictor for outcomes after reduced-intensityallogeneic hematopoietic cell transplantation. Biol Blood MarrowTransplant 14(11):1209-16, 2008.* # Odenike OM, Larson RA, Gajria D, Dolan ME, Delaney SM, KarrisonTG, Ratain MJ, Stock W. Phase I study of the ribonucleotide reductaseinhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP)in combination with high dose cytarabine in patients with advancedmyeloid leukemia. Invest New Drugs 26(3):233-9, 2008.* Wetzler M, Donohue KA, Odenike OM, Feldman EJ, Hurd DD, StoneRM, Westerfelt P, Bloomfield CD, Larson RA. Feasibility of administeringoblimersen (G3139, Genasense) with imatinib mesylate in patients withimatinib resistant chronic myeloid leukemia--Cancer and leukemia groupB study 10107. Leuk Lymphoma 49(7):1274-8, 2008.* # Odenike OM, Alkan S, Sher D, Godwin JE, Huo D, Brandt SJ, GreenM, Xie J, Zhang Y, Vesole DH, Stiff P, Wright J, Larson RA, Stock W.Histone deacetylase inhibitor romidepsin has differential activity in corebinding factor acute myeloid leukemia. Clin Cancer Res 14(21):7095-101,2008.Onel, Kenan MD, PhD* # Ellis NA, Huo D, Yildiz O, Worrillow LJ, Banerjee M, Le Beau MM,Larson RA, Allan JM, Onel K. MDM2 SNP309 and TP53 Arg72Prointeract to alter therapy-related acute myeloid leukemia susceptibility.Blood 112(3):741-9, 2008.Kuptsova N, Chang-Claude J, Kropp S, Helmbold I, Schmezer P, vonFournier D, Haase W, Sautter-Bihl ML, Wenz F, Onel K, Ambrosone CB.Genetic predictors of long-term toxicities after radiation therapy forbreast cancer. Int J Cancer 122(6):1333-9, 2008.Molecular Genetics& HematopoiesisUCCRC SCIENTIFIC REPORT 200939